Fractional Exhaled Nitric Oxide (FeNO)

Fractional Exhaled Nitric Oxide (FeNO) testing measures the level of nitric oxide in a patient’s exhaled breath, serving as a non-invasive marker of airway inflammation. Using the advanced NObreath FeNO Monitor, this test helps assess how well asthma medications are working and predicts the risk of future asthma attacks. At IDC, FeNO testing is quick, painless, and designed to support accurate diagnosis and personalized asthma management.                                                                                                                                                                                                                                                        

Interpreting FeNO Results

FeNO levels are grouped into low, moderate, and high ranges. These levels help doctors understand the degree of airway inflammation and make informed decisions for accurate diagnosis and effective asthma management in both adults and children.

Aiding in Diagnosis:

For patients with respiratory symptoms, FeNO testing can help to differentiate between various conditions

• Low FeNO levels may indicate non-allergic asthma or alternative diagnoses like vocal cord dysfunction, bronchiectasis, or cardiac disease.
• High FeNO levels strongly suggest allergic asthma or other allergic respiratory conditions.

Guiding Asthma Management:

In diagnosed asthma patients, FeNO monitoring helps to optimize treatment.

• Low levels suggest good control and may allow for reduction in inhaled corticosteroid (ICS) dosage.
• Intermediate levels indicate a need for careful clinical evaluation and potential adjustment of therapy.
• High levels point to ongoing inflammation, necessitating a review of medication adherence, inhaler technique, or potential increase in ICS dose.

Personalized Care Approach:

IDC’s implementation of Fractional Exhaled Nitric Oxide (FeNO) testing aligns with our motto: “Correct Diagnosis, Correct Treatment.” This technology enables a more personalized approach to asthma care, allowing clinicians to:

• Predict the likelihood of steroid responsiveness.
• Monitor treatment effectiveness over time.
• Assess adherence to prescribed medications.
• Identify patients at risk for asthma exacerbations.

Considerations & Limitations:

FeNO testing is safe and non-invasive, but results can be influenced by factors like smoking or obesity. It is most effective when interpreted along with your medical history and other tests by our experts, ensuring accurate diagnosis and management.

The Future Of Asthma Care:

By offering advanced diagnostics like FeNO testing, IDC is at the forefront of respiratory care. This technology represents a significant step towards more precise, individualized asthma management strategies. As we continue to understand the complexities of asthma, tools like FeNO monitoring will play an increasingly crucial role in improving patient outcomes. By analyzing each breath, we are gaining a better understanding of asthma, helping to improve the health and well-being of millions of people worldwide.